CD19 and B-cell chronic lymphocytic leukemia: After receiving anti‐CD19 decorated CRA‐NK cell therapy, 73% of patients with recurrent or intractable CD19‐positive malignancy (chronic lymphocytic leukemia or non‐Hodgkin's lymphoma) benefited from the therapy.69